(NASDAQ: DNLI) Denali Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.71%.
Denali Therapeutics's revenue in 2026 is $0.On average, 22 Wall Street analysts forecast DNLI's revenue for 2026 to be $4,558,712,409, with the lowest DNLI revenue forecast at $901,434,035, and the highest DNLI revenue forecast at $12,281,007,880. On average, 21 Wall Street analysts forecast DNLI's revenue for 2027 to be $23,197,177,389, with the lowest DNLI revenue forecast at $5,439,688,141, and the highest DNLI revenue forecast at $59,581,237,254.
In 2028, DNLI is forecast to generate $72,106,793,213 in revenue, with the lowest revenue forecast at $24,556,306,466 and the highest revenue forecast at $147,271,230,372.